In 2005 we developed and transferred 2 processes, and in 2006 we developed and transferred 3 processes to ScinoPharm Taiwan. We are currently working on the complete process development of four Generic APIs .

ScinoPharm Generic API's that SPK developed part, or all of the process:

• Gemcitabine (full API process)
• Risperidone (full API process)
• Tamsulosin (full API process)
• Zolpidem (full API process)
• Topiramate (full API process)
• Fulvestrant (key intermediate process)
• Paclitaxel and Docetaxel (side chain process)
• Galantamine (key intermediate process)
• Azacitidine (full API process)

Generic API's being developed at SPK:

• Bimatoprost
• Travoprost
• Decitabine

Non-API products developed at SPK:

• Sharpless's (DHQ)₂-PHAL chiral dihydroxylation ligand.
• Benzophenone ethyl glycinate imine
• (R) - and (S)-1-(3-chlorophenoxy)-3-mercaptopropan-2-ol